• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

By: Adaptive Biotechnologies via GlobeNewswire
February 05, 2025 at 16:05 PM EST

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

  • BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
    Participating on Wednesday, February 12, 2025
  • TD Cowen 45th Annual Health Care Conference in Boston, MA
    Fireside chat on Monday, March 3, 2025, at 11:10 a.m. Eastern Time

Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com


Primary Logo

More News

View More
Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?
Today 13:41 EDT
Via MarketBeat
Topics Earnings
Tickers T TMUS VZ
AST SpaceMobile: A New Asset Class Held Down by Outdated Models
Today 13:31 EDT
Via MarketBeat
Tickers ASTS KTOS T VOD
What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?
Today 12:19 EDT
Via MarketBeat
Tickers KSS OPEN
5 Stocks to Buy and Hold for the Rise of Physical AI
Today 11:14 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMBA AMD NVDA SYM
The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying
Today 11:10 EDT
Via MarketBeat
Tickers ENR MAGN SDHC
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap